Sun Pharma Agrees to Acquire Organon in $12 Billion Deal
Sun Pharmaceutical Industries Ltd. has agreed to acquire Organon & Co. for $12 billion, marking one of the largest outbound deals by an Indian company. The deal offers a 60% premium over Organon’s stock price and is expected to expand Sun Pharma’s global reach and specialty drug portfolio. Organon specializes in women’s health, and the acquisition is part of Sun Pharma’s strategic shift toward branded drugs.
Tickers: $OGN
Topics: Corporate Strategy Global Expansion Mergers and Acquisitions Pharmaceutical Industry